Regulations.gov document
Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics…
Notice · FDA-2022-D-0235 · posted Jun 27, 2022
Key facts
| Document ID | FDA-2022-D-0235-0001 |
|---|---|
| Title | Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics; Draft Guidance for Industry; Availability |
| Document type | Notice |
| Subtype | Notice of Availability |
| Agency | FDA |
| Docket | FDA-2022-D-0235 |
| Posted | Jun 27, 2022 |
| Federal Register citation | 87 FR 38161 |
| FR document number | 2022-13606 |
| Effective date | Jun 27, 2022 |
At a glance
- 1–9 Pages
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: